According to a study in the New England Journal of Medicine, a single dose of baloxavir marboxil was superior to placebo in controlling influenza symptoms in patients with uncomplicated disease.
Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease, and has demonstrated activity in preclinical models with both influenza types A and B, including resistant strains. A phase 2 and phase 3 study were conducted to assess the efficacy and safety of baloxavir in patients with uncomplicated influenza.
The median time to alleviating symptoms was significantly shorter in each of the baloxavir dose groups (54.2 hours in the 10-mg group, 51.0 hours in the 20-mg group, and 49.5 hours in the 40-mg group) vs placebo (77.7 hours).
